Universal 'Off-the-Shelf' cell therapy tested as potential reset for stubborn autoimmune diseases
NCT ID NCT07507201
Summary
This early-phase study is testing a new cell therapy called QT-219C for people with severe autoimmune diseases that haven't responded to standard treatments. The therapy uses genetically modified immune cells from healthy donors (not the patient) designed to target and remove harmful B cells. Researchers aim to see if this one-time infusion is safe and can help control diseases like lupus, severe kidney disorders, and scleroderma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310052, China
Conditions
Explore the condition pages connected to this study.